Abstract
Quercetin, a secondary metabolite and bioflavonoid, has been explored in recent times for its anti-diabetic potential owing to its wide pharmacological benefits, including antioxidant, anti-inflammatory, anti-allergic, cardiovascular protection, anti-lipidemic, and anti-arthritic properties. The presence of five hydroxyl groups contribute to its therapeutic properties by lowering blood glucose levels, increasing insulin production, improving pancreatic beta cells, and increasing glucose tolerance. Due to its antidiabetic efficacy in clinical studies, similar to other marketed drugs, studies have been conducted on the co-administration of quercetin with metformin, liraglutide, and resveratrol producing marked changes in serum glucose levels synergistically. Furthermore, they have the potential to combat adverse effects such as hypoglycaemia and hypolipidemia caused by other antidiabetic drugs. The mechanistic pathway by which quercetin causes reduced glucose levels is not clearly understood and, in this review, we discuss in detail the predictive pathways by which quercetin executes its anti-oxidant and anti-diabetic efficacy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
